These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 30555553)

  • 1. V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.
    Duan X; Yang S; Zhang L; Yang T
    Theranostics; 2018; 8(19):5379-5399. PubMed ID: 30555553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
    Thudium CS; Jensen VK; Karsdal MA; Henriksen K
    Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
    Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
    Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.
    Yuan FL; Li X; Lu WG; Li CW; Li JP; Wang Y
    Mol Biol Rep; 2010 Oct; 37(7):3561-6. PubMed ID: 20182803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.
    Kartner N; Yao Y; Li K; Crasto GJ; Datti A; Manolson MF
    J Biol Chem; 2010 Nov; 285(48):37476-90. PubMed ID: 20837476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the osteoclast V-ATPase by small interfering RNAs.
    Hu Y; Nyman J; Muhonen P; Väänänen HK; Laitala-Leinonen T
    FEBS Lett; 2005 Sep; 579(22):4937-42. PubMed ID: 16115623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iejimalides show anti-osteoclast activity via V-ATPase inhibition.
    Kazami S; Muroi M; Kawatani M; Kubota T; Usui T; Kobayashi J; Osada H
    Biosci Biotechnol Biochem; 2006 Jun; 70(6):1364-70. PubMed ID: 16794315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine ameloblasts are immunonegative for Tcirg1, the v-H-ATPase subunit essential for the osteoclast plasma proton pump.
    Bronckers AL; Lyaruu DM; Bervoets TJ; Medina JF; DenBesten P; Richter J; Everts V
    Bone; 2012 Apr; 50(4):901-8. PubMed ID: 22245629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption.
    Wu H; Xu G; Li YP
    J Bone Miner Res; 2009 May; 24(5):871-85. PubMed ID: 19113919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
    Farina C; Gagliardi S
    Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional complementation of V-ATPase a subunit isoforms in osteoclasts.
    Matsumoto N; Sekiya M; Fujimoto Y; Haga S; Sun-Wada GH; Wada Y; Nakanishi-Matsui M
    J Biochem; 2021 Apr; 169(4):459-466. PubMed ID: 33135054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity.
    Ochotny N; Van Vliet A; Chan N; Yao Y; Morel M; Kartner N; von Schroeder HP; Heersche JN; Manolson MF
    J Biol Chem; 2006 Sep; 281(36):26102-11. PubMed ID: 16840787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.
    Crasto GJ; Kartner N; Yao Y; Li K; Bullock L; Datti A; Manolson MF
    J Cell Biochem; 2013 Apr; 114(4):929-41. PubMed ID: 23129004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The V-ATPase
    Chu A; Zirngibl RA; Manolson MF
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor.
    Toro EJ; Ostrov DA; Wronski TJ; Holliday LS
    Curr Protein Pept Sci; 2012 Mar; 13(2):180-91. PubMed ID: 22044158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy.
    Ochotny N; Voronov I; Owen C; Aubin JE; Manolson MF
    J Cell Biochem; 2013 Dec; 114(12):2823-33. PubMed ID: 23908015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversity of proton pumps in osteoclasts: V-ATPase with a3 and d2 isoforms is a major form in osteoclasts.
    Matsumoto N; Daido S; Sun-Wada GH; Wada Y; Futai M; Nakanishi-Matsui M
    Biochim Biophys Acta; 2014 Jun; 1837(6):744-9. PubMed ID: 24561225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
    Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
    J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.